Chemotherapy-Activated Cells for Targeted Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell therapy methods for tissue repair lack specificity and efficiency, often requiring expensive genetic modifications and growth factors that can increase toxicity and immunocompatibility, delaying tissue regeneration and wound healing.
Innovation Solution
Activating mesenchymal stem cells, macrophages, and other cell types using specific chemotherapy agents, either directly or through conditioned media, to induce tissue regeneration and repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If growth factors and cytokines are used to activate effector cells, then cell activation is achieved, but toxicity and immunocompatibility increase
Solution Approach 1:
The patent changes the chemical parameters of activation by replacing traditional growth factors and cytokines with chemotherapy agents. This parameter substitution achieves cell activation while avoiding the toxicity and immunocompatibility issues associated with conventional activation methods.
Solution Approach 2:
The patent uses conditioned media containing chemotherapy agents to activate cells, creating a simplified copy of the activation process that eliminates the need for direct application of toxic growth factors and cytokines, thereby reducing harmful effects while maintaining activation efficiency.
2Reliability
If genetic modifications are applied for cell activation, then cell activity is enhanced, but cost and complexity increase
Solution Approach 1:
The patent employs chemotherapy agents as temporary, non-permanent activation tools rather than permanent genetic modifications. These agents provide the necessary cell activation without requiring complex, expensive genetic engineering, aligning with the principle of using simpler, shorter-lived solutions.
Solution Approach 2:
The patent replaces the complex biological system of genetic modification with a simpler chemical activation approach using chemotherapy agents. This substitution eliminates the need for sophisticated genetic engineering infrastructure and procedures while achieving the desired cell activation.
3Reliability
If conventional cell therapy methods are used, then tissue repair is attempted, but specificity and efficiency are insufficient
Solution Approach 1:
The patent applies chemotherapy agents locally to activate effector cells at the specific site of tissue damage. This localized activation ensures that only the relevant cells are activated with high specificity, avoiding the non-specific effects of conventional cell therapy methods and enhancing overall efficiency.
Data Source
AI summary
The invention relates to an activating composition comprising a cell, which may be any cell type used for cell therapy, wherein the cell is activated by a chemotherapy agent. Further, there is provided an activating composition comprising a supernatant of a composition comprising a cell, which may be any cell type used for cell therapy, wherein the cell is activated by a chemotherapy agent and wherein the supernatant is used as a therapy. The invention further provides methods for treating or preventing a disease or a condition comprising the use of the activated composition.